Valensa ~ Eye Pro MD

GENEVAValensa International introduced a new eye-health formulationEye Pro MD that combines carotenoids astaxanthin, lutein and zeaxanthin; and features a proprietary omega-3/phospholipid delivery system, as well as vitamin D3. The formulation was developed based on the results from the CARMIS (Carotenoids and Antioxidant in Age Related Maculopathy Italian Study) clinical trial published in Ophthalmology in 2008.

Valensa holds the rights to the University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye-health supplement applications and has begun a broad outlicensing program in conjunction with its Zanthin® brand Natural Astaxanthin ingredient. Eye Pro MD will be introduced to the market with a similar outlicensing program. Valensa was a recent recipient of a 2009 North American Frost & Sullivan Award for Customer Value Enhancement for its work in developing the global eye health market. Its natural astaxanthin is extracted using ultra-high pressure supercritical CO2 in an allergen-free certified organic facility in Florida. The companys O2B Peroxidation Blocker stabilization technology, assures a four-year shelf life for its astaxanthin extract.

Valensa is currently designing a multi-arm eye health care clinical trial that includes a standalone arm for astaxanthin to further explore its properties and utility in eye healthcare in conjunction with a second arm exploring the benefits of mixed carotenoids and advanced omega-3 delivery systems.